חזרה לתוצאות החיפוש

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE4

מצבים רפואיים

Prostate Cancer

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • Mayo Clinic Arizona, Scottsdale, Arizona, United States

    Study coordinator · 480-301-8300
    Contact: Principal Investigator (Cassandra Moore)

  • St. Joseph Hospital, Orange, California, United States

    Contact: Principal Investigator (Timothy Byun)

  • Providence Saint Johns Health Ctr, Santa Monica, California, United States

    Contact: Principal Investigator (Przemyslaw Twardowski)

  • University of Colorado, Aurora, Colorado, United States

    Contact: Principal Investigator (Muthiah Nachiappan)

  • Hartford Hospital, Hartford, Connecticut, United States

    Contact: Principal Investigator (Andrew Salner)

  • VA Medical Center, Washington D.C., District of Columbia, United States

    Study coordinator · 202-745-8457
    Contact: Principal Investigator (Frank Liu)

  • Mayo Clinic Jacksonville, Jacksonville, Florida, United States

    Contact: Principal Investigator (Winston Tan)

  • University Cancer and Blood Center LLC, Athens, Georgia, United States

    Study coordinator · 706-353-2990
    Contact: Principal Investigator (Petros Nikolinakos)

  • Parkview Research Center, Fort Wayne, Indiana, United States

    Contact: Principal Investigator (Brian Chang)

  • Tulane Cancer Center, New Orleans, Louisiana, United States

    Study coordinator · 504-585-6077
    Contact: Principal Investigator (Brian Lewis)

  • Ochsner Clinic Foundation, New Orleans, Louisiana, United States

    Study coordinator · 504-842-6044
    Contact: Principal Investigator (Stephen Bardot)

  • Corewell Health William Beaum Hosp, Royal Oak, Michigan, United States

    Contact: Principal Investigator (Andrew Thompson)

  • Mayo Clinic Rochester, Rochester, Minnesota, United States

    Contact: Principal Investigator (Brian Costello)

  • University of Mississippi Med Ctr, Jackson, Mississippi, United States

    Study coordinator · +1 601 815 5374
    Contact: Principal Investigator (John Clark Henegan)

  • Wash U School of Medicine, St Louis, Missouri, United States

    Contact: Study coordinator (Lindsey Mayer) · lindseymayer@wustl.edu
    Contact: Principal Investigator (Hyun Kim)

  • Urology Cancer Center PC, Omaha, Nebraska, United States

    Study coordinator · 402-697-2229
    Contact: Principal Investigator (Luke Nordquist)

  • Nebraska Cancer Specialists, Omaha, Nebraska, United States

    Contact: Principal Investigator (Ralph Hauke)

  • Montefiore Medical Center, The Bronx, New York, United States

    Contact: Principal Investigator (Benjamin A Gartrell)

  • Duke University Medical Center, Durham, North Carolina, United States

    Contact: Principal Investigator (Daniel J George)

  • Cleveland Clinic Foundation, Cleveland, Ohio, United States

    Study coordinator · 216-444-0441
    Contact: Principal Investigator (Shilpa Gupta)

  • Univ of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

    Contact: Principal Investigator (Leonard Appleman)

  • Univ of Texas Southwest Med Center, Dallas, Texas, United States

    Contact: Principal Investigator (Kevin Courtney)

  • UT Health Science Center, Houston, Texas, United States

    Contact: Principal Investigator (Bo Chen)

  • Onco Hemato Asso of SW Virginia, Roanoke, Virginia, United States

    Study coordinator · 540-774-8660
    Contact: Principal Investigator (David Buck)

  • Novartis Investigative Site, Linz, Austria

  • Novartis Investigative Site, Vienna, Austria

  • Novartis Investigative Site, Ghent, Belgium

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Olomouc, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Lyon, France

  • Novartis Investigative Site, Essen, Germany

  • Novartis Investigative Site, München, Germany

  • Novartis Investigative Site, Rostock, Germany

  • Novartis Investigative Site, Nijmegen, Gelderland, Netherlands

  • Novartis Investigative Site, Maastricht, Limburg, Netherlands

  • Novartis Investigative Site, Delft, South Holland, Netherlands

  • Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona, Spain

  • Novartis Investigative Site, Sabadell, Barcelona, Spain

  • Novartis Investigative Site, Majadahonda, Madrid, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Gothenburg, Sweden

  • Novartis Investigative Site, Stockholm, Sweden

  • Novartis Investigative Site, Sutton, Surrey, United Kingdom

  • Novartis Investigative Site, Barnet, United Kingdom

  • Novartis Investigative Site, Cambridge, United Kingdom

  • Novartis Investigative Site, Glasgow, United Kingdom

  • Novartis Investigative Site, Middlesbrough, United Kingdom

מובילי המחקר

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)